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Abstract A considerable number of agents with chemo-
therapeutic potentials reported over the past years were
shown to interfere with the reactions of DNA topoisome-
rases, the essential enzymes that regulate conformational
changes in DNA topology. Gossypol, a naturally occurring
bioactive phytochemical is a chemopreventive agent
against various types of cancer cell growth with a reported
activity on mammalian topoisomerase II. The compounds
targeting topoisomerases vary in their mode of action; class
I compounds act by stabilizing covalent topoisomerase-
DNA complexes resulting in DNA strand breaks while
class II compounds interfere with the catalytic function of
topoisomerases without generating strand breaks. In this
study, we report Gossypol as the interfering agent with type
I topoisomerases as well. We also carried out an extensive
set of assays to analyze the type of interference manifested
by Gossypol on DNA topoisomerases. Our results strongly
suggest that Gossypol is a potential class II inhibitor as it
blocked DNA topoisomerase reactions with no conse-
quently formed strand breaks.
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Introduction
Gossypol [GSP; 2,20-bis(8-Formyl-1,6,7-trihydroxy-5-iso-
propyl-3-methylnaphthalene)] is a natural polyphenol
derived from cotton plant (Gossypium, Malvaceae) [1–3]. It
is a promising compound with a number of chemothera-
peutic potentials [4]. Gossypol was reported to inactivate
intracellular dehydrogenases, protein kinases, and type II
DNA topoisomerases [5–7]. Among these enzymes, DNA
topoisomerases gained a considerable attention over the
past years as they are the cellular targets of many clinically
important agents [8–10]. These enzymes are found in
prokaryotes, eukaryotes, viral systems, and cellular
organelles such as mitochondria and chloroplasts with
important roles in replication, transcription, recombination,
and repair [10]. Topoisomerases regulate the DNA topol-
ogy with concerted breakage and reunion of DNA strands
[8]. Two types of topoisomerases based on their reaction
mechanisms are known; type I topoisomerases introduce
single-stranded breaks while type II topoisomerases intro-
duce double-stranded breaks in the DNA molecules during
their catalytic cycles [11].
Since the identification of Camptothecine (CPT) from
Camptotheca acuminata as topoisomerase-targeting com-
pound, several compounds with therapeutical potential were
analyzed through topoisomerase reactions [12–19]. How-
ever, biological activity assays employing DNA topoi-
somerases in vast majority of these studies are limited to
supercoil relaxations, a well-known approach to monitor
either type I or type II activities in the presence of a test
compound. Given the information obtained with such assays,
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the results are not conclusive enough to predict the type of
interaction of the test compound with enzyme–DNA com-
plexes. This is an important issue because topoisomerase-
targeting anticancer drugs are divided into two classes that
vary widely in their mechanisms of actions. The class I drugs
include acridines, anthracyclines, actinomycins, ellipticines,
alkaloids, epipodophyllotoxins, isoflavodins, and quino-
lones, collectively called as ‘‘topoisomerase poisons’’
because they act by stabilizing covalent topoisomerase-
DNA complexes. Class II-drugs, by contrast, interfere with
the catalytic function of the enzyme without stabilizing the
covalent DNA-enzyme complex. The drugs in this class are
referred to as ‘‘topoisomerase inhibitors.’’ The main topoi-
somerase inhibitors are coumarin antibiotics and fostriecin
analogs [9]. Based on the biological activity reports on GSP,
our laboratory carried out an extended set of analyses using
topoisomerases in the absence or the presence of varying
concentrations of this compound. We aimed to identify if the
effect of GSP would cover other topoisomerases as well as
clarifying the type of the detected interference of GSP on
these enzymes by employing supercoil relaxations, decate-
nations, strand cleavage, and covalent–complex analyses.
Our results strongly suggested that GSP has a potential to be
considered as class II compound, interfering with the cata-
lytic functions of both type I and type II topoisomerases
without generating strand breaks.
Materials and Methods
Plasmid Supercoil Relaxation Assays
Plasmid supercoil relaxation assays were done out as
described [20]. Briefly, 20 lL of reaction mixture con-
tained 500 ng of superhelical circular (sc) plasmid DNA
and one unit (u) of either calf thymus type I or mammalian
type II topoisomerase (Inspiralis, Norwich, UK) in reaction
buffers [35 mM Tris–HCl (pH 8.0), 72 mM KCl, 5 mM
MgCl2, 5 mM dithiothreitol (DTT), 5 mM spermidine, and
0.1 % bovine serum albumin for type I topoisomerase and
50 mM Tris–Cl (pH 8.0), 120 mM KCl, 10 mM MgCl2.
0.5 mM ATP, 0.5 mM DTT for type II topoisomerase] in
the presence or the absence of the varying concentrations
of GSP (Sigma-Aldrich, St. Louis, MO, USA), dissolved in
100 % dimethylsulfoxide (DMSO). Reactions were ter-
minated with stop buffer (5 % sarkosyl, 0.0025 % bro-
mophenol blue, 25 % glycerol) and relaxation products
were seperated on 1 % agarose gel in TAE buffer [40 mM
Tris–acetate and 1 mM EDTA (pH 8.0)] in a horizontal
electrophoresis apparatus (5 V/cm) (Thermo, Massachu-
setts, USA) and photographed under UV light after stain-
ing in ethidium bromide (Etd–Br) solution (0.5 lg/mL).
DNA bands were quantified from gel photo images using
BioRad Multianalyst (ver. 1.1) (Vilber Lourmat, Paris,
France). The relationship between the binding of Etd–Br
and the amount of fluorescence given by sc and relaxed
DNA (rlx DNA) under UV light was carried out as
described [21]. One unit of enzyme activity (Inspiralis,
Norwich, UK) was taken as the activity removing the su-
percoils from 500 ng of sc plasmid substrate pBR322 at
37 C in 30 min. The IC50 values, the concentration of the
test compound that reveals 50 % interference on the
topoisomerase reactions were calculated as described [22].
DNA Minicircle Decatenation Assays
Decatenation assays were carried out using 200 ng kinetoplast
DNA (kDNA) substrate and one unit of either topoisomerase II
or topoisomerase IV (Topogen, Florida, USA) in a final volume
of 20 lL in reaction buffer, composed of 50 mM Tris–Cl (pH
8.0), 120 mM KCl, 10 mM MgCl2. 0.5 mM ATP, 0.5 mM
DTT. Reactions were terminated with stop buffer (5 %
sarkosyl, 0.0025 % bromophenol blue, 25 % glycerol) and
electrophoretic analyses of kDNA were performed using 1 %
agarose gel containing Etd–Br (0.5 lg/mL). Resolution of
decatenated DNA products were monitored as stated above.
One unit of type II activity was defined as the amount of
enzyme decatenating 200 ng of kDNA in 15 min at 37 C.
Average band intensities were calculated from three indepen-
dent reactions in both type I and type II topoisomerase assays.
Camptothecin and Etoposide were used as positive controls for
topoisomerase I and topoisomerase II assays, respectively.
DNA Strand Break and Covalent Complex Analyses
DNA strand breaks were analyzed in 30 lL reaction vol-
umes containing 500 ng substrat DNA (pBR322 or pRYG)
using 4–20 units of enzyme.The reactions were carried out
at 37 C for 15 min and terminated by the addition of 1 %
sodium dodecyl sulfate (SDS) and 0.5 lg/mL Proteinase K
(Prot-K). Following the extraction of samples with phe-
nol:chloroform:isoamylalcohol (PCI) (25:24:1 v/v), for-
mation of linear DNA was monitored using 1 % agarose
gel in the presence of 0.5 lg/mL Etd–Br. Covalent com-
plex analyses were carried out as described above except
that the reactions were analyzed both in the presence and
the absence of Prot-K. All the figures submitted as the
results of activity assays with topoisomerases in the pres-
ence of GSP were representative for the reactions, each
experiment was repeated twice.
Results and Discussion
We carried out biochemical assays for plasmid DNA
nicking and DNA decatenation to monitor type I and type
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II topoisomerases, respectively, in the presence or the
absence of GSP. The former assay relies on the ability of
topoisomerases to relax sc DNA substrates. Interference by
GSP was monitored according to the migration pattern of
substrate and product DNA molecules on agarose gel. A
representative supercoil relaxation assay using decreasing
concentrations of GSP is given in Fig. 1. Supercoil plasmid
substrate, pBR322 (Fig. 1, lane 1) was relaxed by topo I
(Fig. 1, lane 2) in the absence of GSP while this activity
was not significantly influenced by 10 % DMSO, used in
dissolving GSP (Fig. 1, lane 3). The relaxation of super-
coils was profoundly affected in the presence of 0.1 volume
of 1 and 0.5 mM GSP (Fig. 1, lanes 4 and 5, respectively).
The faster migrating sc band was decreased when GSP was
diluted to 0.2 and 0.1 mM (Fig. 1, lanes 6 and 7, respec-
tively). The interference disappeared in the presence of
0.05 mM of GSP (Fig. 1, lane 8). Densitometric calcula-
tions of relative band intensities showed that the interfer-
ence was as high as 100–95 % at 0.1 volume of 1 and
0.5 mM GSP concentrations, respectively, and this value
gradually decreased to 70–65 % upon serial dilutions while
approaching to 0 % at 0.1 volume of 0.05 mM GSP, which
gave rise to an IC50 value of 15 lM (Fig. 1). The inter-
ference obtained by GSP was in a comparable degree to
that of CPT (data not shown). Residual nicked-circular
DNA present in plasmid was taken into account during
quantitative evaluations.
We next employed decatenation assays in the presence
or the absence of GSP using a type II enzyme, topo IV.
Decatenation is a type II topoisomerase-specific assay
employing kDNA, the mitochondrial DNA of Crithidia
fasciculata as a catenated network of DNA rings, the
majority of which are 2.5 kb monomers [23]. The assay
takes advantage of inclusion of Etd–Br thereby seperating
open-circular (OC) monomers from covalently closed cir-
cular (CCC) DNA population. As seen in Fig. 2, the kDNA
was too large to enter the gel (Fig. 2, lane 1), while the
enzyme yielded monomeric DNA rings (Fig. 2, lane 2). A
remarkable degree of interference was obtained on topoi-
somerase IV-catalyzed decatenation in the presence of 0.1
volume of 1 and 0.1 mM GSP (Fig. 2, lanes 3 and 4,
respectively) while diluting GSP to 0.2 mM diminished the
interference (Fig. 2, lane 5) as the banding pattern of the
latter lane approached to decatenation activity of enzyme
(Fig. 2, lane 2) obtained in the absence of GSP. Quantita-
tive evaluation of the interference revealed an average of
90, 78, and 27 % change in decatenation when 1, 0.1, and
0.2 mM GSP in respective order were included in reaction
mixture with an estimated IC50 value of 15 lM (Fig. 2).
We obtained a comparable effect of GSP on topoisomerase
II-catalyzed decatenation assays as well (data not shown).
Both assays given above are frequently employed in
topoisomerase-based biological activity studies; however,
the results from such assays do not lead to identify the
pathway test compound follows in exerting its function.
We next investigated GSP to identify whether its inclusion
in the reaction mixture resulted in the formation of DNA
strand breaks or it was the enzyme’s catalytic properties
changed by GSP. We set the topoisomerase II reactions as
defined above using pRYG plasmid, a 54 bp DNA sub-
strate of high affinity to topo II with repeating purine and
pyrimidine bases, and then employed 1 % SDS to termi-
nate enzyme’s catalysis. Following the Prot-K digestion
and PCI extraction, we monitored DNA strand breaks by
the formation of linearized DNA. Because of the nature of
strand break analyses, we used a higher amount of enzyme
(4–20 units per reaction) in these assays and employed
Etoposide, a known topo II-targeting agent as a positive
control. Fig. 3 shows a representative agarose gel run in the
presence of Etd–Br. Supercoiled pRYG substrate (Fig. 3a,
lane 2) was relaxed with topoisomerase II (Fig. 3a, lane 3)
without a significant effect by DMSO (Fig. 3a, lane 4). The
control compound yielded a remarkable amount of DNA
strand breaks (Fig. 3a, lane 5) that showed the same
Fig. 1 The effect of Gossypol on supercoil relaxation activity of
mammalian DNA topoisomerase I. A representative agarose gel
photograph of supercoil relaxation in the presence of varying
concentrations of Gossypol; lane 1, pBR322; lane 2, pBR322 with
1 u of DNA topoisomerase I; lane 3, same as lane 2 in the presence
10 % DMSO; lanes 4–8, relaxations in the presence of 0.1 volume of
1, 0.5, 0.2, 0.1, and 0.05 mM Gossypol, respectively (Fig. 1).
Densitometric quantification of the reaction profile is shown next to
gel photograph
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migration pattern with linear pRYG (Fig. 3a, lane 1).
However, no strand breaks was identified in the presence of
2.5 mM GSP (Fig. 3a, lane 6) as the reaction yielded a
banding pattern similar to negative control that did not
include the enzyme (Fig. 3a, lane 2). Increasing the con-
centration of GSP did not change the effect and the results
were confirmed by monitoring the reactions using non Etd–
Br agarose gels as well as topoisomerase I reactions (data
not shown).
We extended strand breaks experiments to cover the
covalent complex analyses in the absence or the presence of
Prot-K. The rationale in analyzing covalent complexes relies
on the differential partition of protein-bound and protein-
unbound DNA during PCI extraction by including or
excluding Prot-K digestion following the termination of
reactions. We used pBR322 in the same order of reactions as
Fig. 3a during covalent complex analyses (Fig. 3b). Inclu-
sion of 0.1 volume of 2.5 mM Etoposide in topoisomerase II
Fig. 2 A representative
decatenation assay and its
quantitative evaluation of
topoisomerase IV-catalyzed
reaction in the presence of
Gossypol. Agarose gel
photograph of decatenation
activity of topo IV in the
presence of 0.1 volume
of 1 mM (lane 3), 0.1 mM
(lane 4), and 0.02 mM (lane 5)
Gossypol. Lanes 1 and 2
correspond to negative and
positive controls in the absence
of Gossypol. Densitometric
quantification of the reaction
profile is shown on the right
panel
Fig. 3 Representative DNA
strand break and covalent
complex analyses of
topoisomerase II-catalyzed
reactions in the absence or the
presence of Gossypol. a DNA
strand break analyses.
b Covalent complex analyses.
lane 1, linear DNA standard;
lane 2, sc DNA substrate;
lane 3, DNA substrate with
topoisomerase II; lane 4, same
as lane 2 in the presence 100 %
DMSO; lanes 5, 6, same as lane
2 in the presence of 2.5 mM
Etoposide (lane 5) and 10 mM
Gossypol (lane 6). Proteinase K
digestion was omitted in lower
panel of B (see text for detailed
explanation)
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reaction resulted in double strand breaks as monitored with
linearized pBR322 (Fig. 3b, upper lane 5) while the linear
band disappeared if Prot-K digestion was omitted (Fig. 3b,
lower panel, lane 5) indicating that protein-bound DNA was
lost in PCI phase. The effect of DMSO (Fig. 3b, both panels,
lane 4) was independent of Prot-K digestion and comparable
to the positive control lane (Fig. 3b, both panels, lane 3).
Gossypol did not result in the formation of strand breaks
(Fig. 3b, both panels, lane 6). Like banding pattern of 3A, the
reaction in the presence of 10 mM GSP was similar to the
negative control set in the absence of enzyme (Fig. 3b, both
panels, lane 2). Incubation of plasmid DNA with either test
compound or DMSO alone in the absence of enzyme was not
influential on substrate DNA (data not shown); therefore, the
results we obtained were based on the formation of enzyme–
DNA complex.
Concluding Remarks
Different classes of topoisomerase-targeting drugs target
different sites in the formation of the enzyme–DNA complex.
Given the structural diversity of topoisomerase-targeting
drugs, a unified mechanism of action on enzyme–DNA
complex by different compounds can hardly be proposed. Our
results summarized above strongly suggest that GSP is both
type I and type II topoisomerase-targeting agent. Separate
incubation of GSP with enzymes did not alter its activity (data
not shown) and reaction profiles showed gradual change in
topoisomerase reaction products in response to the GSP
concentration, which indicated that the effects we obtained
were attributed to GSP on enzyme–DNA complex. Although
exact characterization of the interaction of GSP with topoi-
somerase-DNA complex requires additional parameters to be
measured, our results exclude the possibility of GSP acting as
topoisomerase poison as no strand breakage was observed
even at relatively high concentrations of GSP. Besides its
chemical composition, our results also exclude the possibility
of GSP acting as groove binding compound. Given the clinical
importance of the catalytic inhibitors of DNA topoisomerases,
GSP is a promising small molecule of natural source with a
potential to be used in anticancer drug development.
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